NEWSROOM

oncology

Immune Therapeutics, Inc. Appoints New Independent Director

Aug 7, 2020

Fort Collins, Co., February 18, 2020 —Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced the appointment of Mr. Michael L. Sander to its Board of Directors who will succeed Jack Brewer who served on the Company’s Board of Directors since 2018 and Edward Teraskiewicz, who served on the Company’s Board of...

read more

Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

Aug 7, 2020

Awaiting completion of FINRA approval process ORLANDO, Fla., February 11, 2020 -- Immune Therapeutics, Inc. (OTC PINK: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announced an update on the pending 1000 to 1 reverse stock split and name change of Immune Therapeutics. Immune Therapeutics originally submitted the reverse and name request for...

read more

Immune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company

Aug 7, 2020

The Planned Acquisition Would Enhance the Management Team, Provide Capital and Bring Additional Oncology Assets to Immune’s Pipeline   ORLANDO, Fla., December 16th, 2019  -- -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a privately held development-stage oncology therapeutics company, today announced that Immune will acquire Aletheia in an all-stock transaction.  Pursuant to completion of a definitive agreement,...

read more

Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change

Aug 7, 2020

    ORLANDO, Fla., October 28, 2019 — – Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies for the treatment of cancer using an immune therapy  and a systems biology approach today announced that its Board of Directors and a majority of its shareholders have approved a reverse stock split of the Company’s issued and outstanding common shares at a ratio of 1,000 to 1 and a...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »